REG - Venture Life Group - Directorate Change

Venture LifeAnnouncement

20/09/2018 07:05

RNS Number : 3208B
Venture Life Group PLC
20 September 2018
 


20 September 2018
Venture Life Group plc
("Venture Life" or the "Company")
 
Directorate Change
 
Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces the appointment of Carl Dempsey as a Non-Executive Director to replace John Sylvester who has stepped down from the Board to focus on his other executive commitments. These Board changes take place with immediate effect.
 
Until recently, Carl was Worldwide Vice President Global Customer Management at Johnson & Johnson ("J&J") where he was responsible for global sales of US$3.6 billion across 22 countries. During his 29 year career at J&J, Carl had particular responsibility for developing the Health and Wellness Partnership strategy. He also led the successful integration of Pfizer Consumer Healthcare across Europe, Africa and the Middle East which included the Listerine mouthwash brand.    
    
Dr Lynn Drummond, Non-Executive Chair of Venture Life, commented: "We are delighted to welcome Carl to the Board. His wide variety of international roles and experience gained in his long career at J&J will no doubt prove to be a valuable asset to the rest of the Board as we seek to continue growing the business both organically and via acquisitions.
 
"On behalf of the Board, I would like to thank John for his contribution to the Company. He has been with Venture Life since our IPO in 2014 and we have appreciated his guidance during this time and we wish him all the best for the future."
 
Further information on Carl Dempsey
 
Carl Douglas Dempsey (aged 56) has in the last five years been a director of Johnson & Johnson Consumer Services (EAME) Limited and is currently a director of Big Blue Bear Limited.
 
There is no further information on Carl Dempsey required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
 
For further information please contact:



Venture Life Group PLC


+44 (0) 1344 742870




Jerry Randall, Chief Executive Officer








Adrian Crockett, Chief Financial Officer   


















Northland Capital Partners Limited (Nominated Adviser and Joint Broker)


+44 (0) 20 3861 6625




Matthew Johnson / Edward Hutton (Corporate Finance)








Vadim Alexandre (Corporate Broking)


















Cenkos Securities plc (Joint Broker)


+44 (0) 207 397 8900




Mark Connelly (Corporate Finance)








Russell Kerr / Michael Johnson (Sales)


















Walbrook PR


  venturelife@walbrookpr.com or + 44 (0) 20 7933 8780




Anna Dunphy / Paul McManus


+44 (0) 7876 741 001 / +44 (0) 7980 541 893

















 
About Venture Life (www.venture-life.com) 
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOABLGDCXDBBGIC